Exploiting drug-disease relationships for computational drug repositioning

Briefings in Bioinformatics

Volumn 12, Issue 4, 2011, Pages 303-311

  Dudley, Joel T ^a   Deshpande, Tarangini ^b   Butte, Atul J ^c  

^a STANFORD UNIVERSITY   (United States)

^b NuMedii   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bioinformatics; Drug development; Drug repositioning; Gene expression; Genomics; Microarrays; Systems biology

Indexed keywords

DRUG;

ALGORITHM; ANIMAL; ARTICLE; BIOLOGY; CHEMISTRY; DRUG DESIGN; DRUG INDUSTRY; DRUG REPOSITIONING; GENERAL ASPECTS OF DISEASE; HUMAN; METHODOLOGY;

ALGORITHMS; ANIMALS; COMPUTATIONAL BIOLOGY; DISEASE; DRUG DESIGN; DRUG INDUSTRY; DRUG REPOSITIONING; HUMANS; PHARMACEUTICAL PREPARATIONS;

ANIMALIA;

EID: 79960796417     PISSN: 14675463     EISSN: 14774054     Source Type: Journal    
DOI: 10.1093/bib/bbr013     Document Type: Article

References (43)

1. Booth B, Zemmel R. Prospects for productivity. Nat Rev Drug Discov 2004;3:451-6.
2. Dimasi JA. New drug development in the United States from 1963 to 1999. Clin Pharmacol Ther 2001;69:286-96.
3. Adams CP, Brantner VV. Estimating the cost of new drug development: Is it really 802 million dollars? Health Aff 2006;25:420-8.
4. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3:673-83.
5. Anand G. 'How drug's rebirth as treatment for cancer fueled price rises: once-demonized thalidomide boosts celgene's sales; patients see costs soar' 2004. New York: The Wall Street J, New York, 2004;15:A1, A18.
6. Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of Type 2 diabetes. DiabetesCare 2000;23:1154-61.
7. Weinstein JN, Myers TG, O'Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275:343-9.
8. Hughes T, Andrews B, Boone C. Old drugs, new tricks: using genetically sensitized yeast to reveal drug targets. Cell 2004;116:5-7.
9. Lum PY, Armour CD, Stepaniants SB, et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 2004;116: 121-37.
10. Kinnamon KE, Rothe WE. Biological screening in the US Army antimalarial drug development program. Am J Trop Med Hyg 1975;24:174-8.
11. Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature 2009;462:175-81.
12. Elvidge S. Getting the drug repositioning genie out of the bottle. Life Sci Leader 2010;14-8.
13. Aronson JK. Old drugs-new uses. BrJ Clin Pharmacol 2007; 64:563-5.
14. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-8.
15. Yardley V, Croft SL. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob Agents Chemother 1997;41:752-6.
16. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
17. Eckert H, Bajorath J. Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. Drug DiscovToday 2007;12:225-33.
18. Noeske T, Sasse BC, Stark H, et al. Predicting compound selectivity by self-organizing maps: cross-activities of metabotropic glutamate receptor antagonists. Chem Med Chem 2006;1:1066-8.
19. Qu XA, Gudivada RC, Jegga AG, et al. Inferring novel disease indications for known drugs by semantically linking drug action and disease mechanism relationships. BMC Bioinformatics 2009;10(Suppl 5):S4.
20. Fourches D, Muratov E, Tropsha A. Trust, but verify: on the importance of chemical structure curation in cheminformatics and QSAR modeling research. J Chem Inf Model 2010;50:1189-204.
21. Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-35.
22. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545-50.
23. Iorio F, Bosotti R, Scacheri E, et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci USA 2010;107:14621-6.
24. Frey BJ, Dueck D. Clustering by passing messages between data points. Science 2007;315:972-6.
25. Wei G, Twomey D, Lamb J, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006;10: 331-42.
26. Chen B, Wild D, Guha R. PubChem as a source of polypharmacology. J Chem Inf Model 2009;49:2044-55.
27. Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br J Pharmacol 2007;152:9-20.
28. Zahler S, Tietze S, Totzke F, et al. Inverse in silico screening for identification of kinase inhibitor targets. Chem Biol 2007; 14:1207-14.
29. Kinnings SL, Liu N, Buchmeier N, et al. Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput Biol 2009;5: e1000423.
30. Chang RL, Xie L, Bourne PE, et al. Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLoS Comput Biol 2010;6: e1000938.
31. Lorber DM, Shoichet BK. Flexible ligand docking using conformational ensembles. Protein Sci 1998;7:938-50.
32. von Eichborn J, Murgueitio MS, Dunkel M, et al. PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res 2010;39(Database issue):D1060-6.
33. Chiang AP, Butte AJ. Systematic evaluation of drug-disease relationships to identify leads for novel drug uses. Clin Pharmacol Ther 2009;86:507-10.
34. Solomon WD, Wroe CJ, Rector AL, et al. A reference terminology for drugs. Proc Amia Symp 1999;152-5.
35. Hu G, Agarwal P. Human disease-drug network based on genomic expression profiles. PLoS One 2009;4:e6536.
36. Li Y, Agarwal P. A pathway-based view of human diseases and disease relationships. PLoS One 2009;4:e4346.
37. Agarwal P, Searls DB. Can literature analysis identify innovation drivers in drug discovery? Nat Rev Drug Discov 2009;8: 865-78.
38. Suthram S, Dudley JT, Chiang AP, et al. Network-based elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets. PLoS Comput Biol 2010;6:e1000662.
39. Segal E, Friedman N, Koller D, et al. A module map showing conditional activity of expression modules in cancer. Nat Genet 2004;36:1090-8.
40. Yang X, Deignan JL, Qi H, et al. Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks. Nat Genet 2009;41:415-23.
41. Dudley JT, Schadt E, Sirota M, et al. Drug discovery in a multidimensional world: systems, patterns, and networks. J Cardiovasc Transl Res 2010;3:438-47.
42. Campillos M, Kuhn M, Gavin AC, et al. Drug target identification using side-effect similarity. Science 2008;321: 263-6.
43. Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Res 2004;32:D267-70.